ICPT2Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced multiple Ocaliva®(obeticholic acid) for PBC and INT-767 data presentations at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), taking place November 11 — 15 in Boston, MA.

“We have numerous presentations at this year’s Liver Meeting, among them an oral presentation examining Ocaliva’s effects on non-invasive fibrosis measurements in patients with PBC,” said David Shapiro, M.D., Intercept’s Chief Medical Officer & Executive Vice President, Development. “Other PBC presentations include an evaluation of Ocaliva data using a long-term prognostic model developed by the UK-PBC Study Group and analyses of Ocaliva’s safety and efficacy in PBC patient populations with end-stage liver disease and renal disease. In addition, we look forward to sharing an analysis of fibrosis data from the FLINT trial in NASH and new preclinical research examining INT-767 — our FXR/TGR5 dual agonist — in animal models of NASH and metabolic disease.”

Intercept also announced its sponsorship of the new TARGET-NASH patient registry, which will advance the understanding of NASH diagnosis and management across multiple populations in a real world setting. As the NASH treatment landscape evolves, the registry will evaluate the safety and effectiveness of new agents across populations not included or underrepresented in Phase 3 clinical trials. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal of Virginia Commonwealth University, Ken Cusi of the University of Florida and Brent Tetri of St. Louis University. The registry is currently enrolling and additional details about TARGET-NASH are available at ClinicalTrials.gov.

In the United States, Ocaliva was recently approved by the FDA for the treatment primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Obeticholic acid is also being investigated for patients with NASH and liver fibrosis, as well as primary sclerosing cholangitis and biliary atresia. (Original Source)

Shares of Intercept closed yesterday at $123.74, down $0.46 or -0.37%. ICPT has a 1-year high of $217.99 and a 1-year low of $89.76. The stock’s 50-day moving average is $155.50 and its 200-day moving average is $151.76.

On the ratings front, ICPT has been the subject of a number of recent research reports. In a report issued on October 24, Oppenheimer analyst Jay Olson maintained a Buy rating on ICPT, with a price target of $200, which represents a potential upside of 62% from where the stock is currently trading. Separately, on October 17, Cowen’s Ritu Baral reiterated a Buy rating on the stock.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jay Olson and Ritu Baral have a yearly average return of 22.4% and 2.1% respectively. Olson has a success rate of 43% and is ranked #880 out of 4178 analysts, while Baral has a success rate of 34% and is ranked #1055.

The street is mostly Bullish on ICPT stock. Out of 14 analysts who cover the stock, 9 suggest a Buy rating, 3 suggest a Sell and 2 recommend to Hold the stock. The 12-month average price target assigned to the stock is $204.67, which represents a potential upside of 65% from where the stock is currently trading.

Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea.